Lung screening registry aims to uncover hidden COPD cases
NCT ID NCT06974981
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is creating a registry of 420 people who are already getting lung cancer screening and may have COPD. Researchers will collect information like breathing tests, CT scans, and symptoms to better understand COPD in this group. The goal is to improve how COPD is found and managed, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 420 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients eligible for lung cancer screening due to their age and history of tobacco use, and have COPD, chronic bronchitis, or emphysema
- Ages
-
50 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * • \* Eligible for lung cancer screening by USPSTF 2021 criteria including age 50-80 years and currently or formerly smoking with at last 20 pack-years of smoking history at the time of consent * Willingness to participate in an observational clinical trial and to be contacted about future ancillary studies that could include interventional clinical trials * Ability to tolerate study procedures * Ability to provide informed consent * Clinical Lung Cancer Screening CT performed at the University of Michigan within the last year * Meets one of the three following criteria: 1) Prior Diagnosis of COPD in the EMR 2) Prior pulmonary function meeting criteria for COPD (FEV1/FVC ≤ 0.70) or 3) LAA\>1% on lung cancer screening CT scan Exclusion Criteria: * The presence of a respiratory condition other than COPD or asthma, or of a comorbid condition that in the judgment of the investigator may be the principal cause of respiratory symptoms (e.g. dyspnea or decreased exercise tolerance)Severe asthma, which is defined as any of the following: * Current (i.e. at the time of the visit) GINA Step 4 or higher therapy (medium dose ICS/LABA or high dose ICS or add-on LAMA; medium dose = \>250 fluticasone propionate =100 fluticasone furoate, \>200 beclomethasone, \>400 budesonide, \>220 mometasone). We will accept low-dose ICS/LABA or medium dose ICS or * 3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months or * One asthma hospitalization in the past 12 months * Concurrent participation in a therapeutic trial where treatment is blinded * Active pregnancy. Documentation of birth control will be required for pre-menopausal women * Cognitive dysfunction that prevents the participant from completing study procedures * BMI \> 35 kg/m2 at baseline, due to the effects of body weight on CT scan quality * Current illicit substance abuse, including cannabis smoking * Any illness expected to cause mortality in the next 3 years * Any implanted metallic devices or prosthesis above the waist that could degrade thoracic CT scan quality * History of thoracic radiation or thoracic surgery with resection of lung tissue * Participants who present with an acute exacerbation of COPD, either solely participant-identified or that has been clinically treated, in the last 30 days can be rescreened for the study once the 30-day window from end of drug therapy has passed * Participants who present with current use of acute antibiotics or steroids can be rescreened for the study \>= 30 days after discontinuing acute antibiotics/steroids. This restriction does not apply to participants who are on chronic prednisone therapy of \<10 mg per day or \<20 mg every other day or participants who are currently on chronic, prophylactic, or suppressive antibiotic therapy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Thomas Jefferson University
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an inhaler boost heart pumping in COPD patients?
- Can zapping the Brain's diaphragm center help COPD breathing?
- Can Device-Preserved donor lungs boost transplant success?
- Can a COPD flare stun the heart? study watches for hidden strain
- Tiny One-Way valves for emphysema under close watch in japan
- Can better training get doctors to talk about what matters most to dying veterans?